摘要骨肉瘤是临床上最常见的一种原发性恶性骨肿瘤,手术和多药联合化疗是主要的治疗方法。本文对2009年第45届美国临床肿瘤学会(American Society of Clinical Oncology,ASCO)年度会议中有关骨肉瘤的研究报道进行综述,从骨肉瘤远期疗效的评价、预后因素分析和化疗方案选择等方面予以述评。
1KAGER L, ZOUBEK A, KASTNER U, et al. Skip metastases in osteosarcoma: experience of the Cooperative Osteosarcoma Study Group[J]. J Clin Oncol, 2006, 24(10):1535-1541.
2JEYS L M, GRIMER R J, CARTER S R, et al. Post operative infection and increased survival in osteosarcoma patients: are they associated[J]. Ann Surg Oncol, 2007, 14(10) :2887-2895.
3PICCI P, MERCURI M, FERRARI S, et al. Survival in high-grade osteosarcoma: hnprovement in a 21-year period at a single institution [J]. J Clin Oncol, 2009, 27(15s) : abstr 10515.
4PETRILLI A S, DE CAMMARGO B, ODONE F V, et al. Fifteen years experience of the Brazilian Ostcosarcoma Treatment Group (BOTG) [J]. J Clin Oncol, 2009, 27( 15s): abstr 10039.
5VAN SCHIE R, HAGLEITNER M, HOOGERBRUGGE P. et al. Overall survival trends in pediatric osteosarcoma patients over the past three decades [J]. J Clin Oncol, 2009, 27 (15s) : abstr 10041.
6LAMOUREUX F, RICHARD P, WITTRANT Y, et al. Therapeutic relevance of osteoprotegerin gene therapy in osteosareoma: blockade of the vicious cycle between tumor celt proliferation and bone resorption [J]. Cancer Res, 2007, 67 ( 15 ) :7308-7318.
7MEYERS P A, SCHWARTZ C L. KRAILO M D, et al. Osteosarcoma : tile addition of muramyl tripeptide to chemotherapy improves overall survival-a report from the children' s oncology group[J]. J Clin Oncol, 2008, 26(4) :633438.
8ANTUNES M, BERNARDO J, SALETE M, et al. Excision of pulmonary metastases of osteogenic sarcoma of the limbs[J]. Eur J Cardiothorac Surg, 1999, 15 ( 5 ) :592-596.
9KIM M S, LEE S Y, LEE T R, et al. Prognostic nomogram for predicting the 5-year probability of developing metastasis after neoadjuvant chemotherapy and definitive surgery for AJCC stage Ⅱ extremity osteosarcoma [J]. Ann Oncol, 2009, 20 ( 5 ) :955-960.
10PETRILLI A S, DE CAMARGO B, FILHO V O, et al. Results of the Brazilian Osteosarcoma Treatment Group Studies Ⅲ and Ⅳ: prognostic factors and impact on survival[J]. J Clin Oncol, 2006, 24(7) :1161-1168.
5Ferguson WS,Harris MB,Goorin AM,et al.Presurgical window of carbop-latin and surgery and multidrug chemotherapy for the treatment of newly diagnosed metastatic or unresectable osteosarcoma:Pediatric Oncology Group Trial[J].J Pediatr Hematol Oncol,2001,23(6):340-348.
6Rosen G,Caparros B,Huvos AG,et al.Preoperative chemotherapy for osteogenic sarcoma:selection of postoperative adjuvant chemotherapy based on the response of the primary tumor top reoperative chemotherapy[J].Cancer,1982,49(6):1221-1230.
7Enneking WF.A system for the functional evaluation of the surgical management of musculoskeletal tumors.Limbsalvage in musculoskeletal oncology[M].New York:Churchill Livingstone,1987:5216.
8Kitareewan S, Blumen S, Sekula D, et al. G0 S2 is an all-trans-retin-oic acid target gene [ J ]. Int J Oncol, 2008,33 (2) :397404.
9Jeys LM, Grimer R J, Carter SR, et al. Post operative infection and increased survival in osteosarcoma patients: are they associated [ J ]. Ann Surg Oncol, 2007,14(10) :2887-2895.
10Munshin C, Tricot G, Desikan R, et al. Clinical aclivity of arsenic trioxide for the treatment of multiple myeloma [ J ]. Leukemia, 2002,16(9) :1835-1837.
